VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naive Patients With Genotype 1 Chronic Hepatitis C Virus Infection.

This is a randomised (study drug assigned by chance), open-label (all persons know the study
drug assignment) multicenter study to evaluate the effectiveness of telaprevir administered
orally as 1125 milligram (mg) twice daily versus 750mg every 8 hours in combination with
Peg-IFN-alfa-2a, administered via intramuscular injection once a week, and ribavirin,
administered as an oral tablet twice a day, in treatment-naïve patients with chronic HCV
genotype 1 infection. Telaprevir will be given orally (by mouth) from Day 1 through Week 12
as 3 tablets (1125mg) twice daily or 2 tablets (750mg) every 8 hours. Peg-IFN-alfa-2a will
be administered once a week as an injection under the skin (180 microgram/week) from Day 1
through Week 24 or 48 (based on the patient's treatment response on week 4). Ribavirin is
administered orally (by mouth) twice daily from Day 1 through Week 24 or 48 (based on the
patient's treatment response on week 4) as 1,000-1,200mg per day.